Medroxyprogesterone
Active ingredient · 3 therapeutic classes
Sold as CLIMANOR · AA-MEDROXY · DEPO-PROVERA
- Drug class
- Progestogens
- Availability
- Prescription only
- Routes
- Oral, Intramuscular
- Markets covered
- 3
- Products on record
- 65
- FDA reports (12 mo)
- 3,393
Overview
Plain-language summary, compiled from the cited regulatory records
Medroxyprogesterone is a progestin [1]. It belongs to the drug class of progestogens [1].
This medication is approved for use by females of reproductive potential to prevent pregnancy [1]. However, its use is not recommended as a long-term birth control method, generally longer than 2 years, unless other options are considered inadequate [1].
In the past 12 months, there were 3,393 adverse event reports associated with this active ingredient [2]. Among the reported adverse events were meningioma, meningioma benign, off-label use, nausea, and device leakage [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 49 | May 29, 2026 |
| CA Canada | Health Canada | 9 | May 19, 2026 |
| US United States | FDA | 7 | May 27, 2026 |
GBUnited Kingdom· MHRA
49 products
Uses
SAYANA PRESS is indicated for long-term female contraception. Each subcutaneous injection prevents ovulation and provides contraception for at least 13 weeks (+/- 1 week). 4). 4), a risk/benefit assessment, which also takes into consideration the decrease in BMD that occurs during pregnancy and/or lactation, should be considered.
4). SAYANA PRESS has not been studied in women under the age of 18 years but data are available for intramuscular depot-medroxyprogesterone acetate (DMPA-IM) 150mg in this population.
How to take
CACanada· Health Canada
9 products
Uses
4 Administration 04/2025 7 WARNINGS AND PRECAUTIONS 04/2025 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES....................................................................................................
2 TABLE OF CONTENTS..................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ...............................................................................
4 1 INDICATIONS............................................................................................................................. 1 Pediatrics .......................................................................................................................
2 Geriatrics ....................................................................................................................... 4 2 CONTRAINDICATIONS.................................................................................................................
USUnited States· FDA
7 products
Uses
INDICATIONS & USAGE
Medroxyprogesterone acetate tablets, USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. 625 mg tablets.
How to take
Drug interactions
Known interactions involving Medroxyprogesterone. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL000571093 · revised April 17, 2026
- [2]Health Canada (DPD) · 02519062 · revised April 23, 2025
- [3]FDA DailyMed · 1020bb60-4f13-4c… · revised May 27, 2026 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.